Login
Theme

About

Hereditary ataxias are a heterogeneous set of severely disabling neurological disorders caused by degeneration of the cerebellum and/or the spinal cord. The prevalence of hereditary ataxias is estimated to 1/20,000 individuals in Europe, and yet there are no specific treatments for most of them.

Our research focuses on understanding the pathophysiology of ataxia, discovering disease biomarkers and developing therapeutic approaches. In addition, in close collaboration with the clinicians, we are developing new diagnostics tools for cerebellar ataxia and identify novel genes causing ataxia.

We are mainly interested in two different recessive ataxias, Friedreich ataxia (FA) and autosomal recessive cerebellar ataxia 2 (ARCA2), linked to two essential mitochondrial pathways: iron-sulfur cluster (ICS) biosynthesis and coenzyme Q10 (CoQ10) biosynthesis, respectively; FA belongs to the family of trinucleotide repeat disorders, which are caused by dynamic mutations that show instability (expansion/contraction) in the germline and in selective somatic cells.

Friedreich ataxia (FA), the most common recessive ataxia, is characterized by progressive gait and limb ataxia associated with hypertrophic cardiomyopathy and an increase incidence in diabetes. The major mutation is a GAA repeat expansion within the first intron of the FXN gene. In FA, the GAA expansion leads to heterochromatinization of the locus resulting in a drastic decrease of transcription of FXN. The disease results from loss of function of FXN gene product, frataxin, a highly conserved mitochondrial protein involved in the biogenesis of ISC, which are essential protein cofactors implicated in numerous cellular functions.

The autosomal recessive cerebellar ataxia 2 (ARCA2) is characterized by cerebellar ataxia and atrophy, and is associated with exercise intolerance. Most patients present a mild deficiency in CoQ10 in muscle biopsies. ARCA2 results from mutations in the ADCK3/COQ8A gene that encodes a mitochondrial protein with a regulatory role in CoQ10 biosynthesis.

Publications

2025
Margaux Haering, Andrea Del Bondio, Helene Puccio, Bianca Habermann, mitoXplorer 3.0, A Web Tool for Exploring Mitochondrial Dynamics in Single-cell RNA-seq Data, Journal of Molecular Biology.
2025
Agnès Conjard-Duplany, Alexis Osseni, Aline Lamboux, Sandrine Mouradian, Flavien Picard, Vincent Mo..., Muscle mTOR controls iron homeostasis and ferritinophagy via NRF2, HIFs and AKT/PKB signaling pathways, Cell Mol Life Sci 2025 Apr; 82(1): 178.
2024
Florent Arbogast, Raquel Sal-Carro, Wacym Boufenghour, Quentin Frenger, Delphine Bouis, Louise Filip..., Epidermal maintenance of Langerhans cells relies on autophagy-regulated lipid metabolism, Journal of Cell Biology.
2024
Federica Pilotto, Andrea del Bondio, Hélène Puccio, Hereditary Ataxias: From Bench to Clinic, Where Do We Stand?, Cells.
2024
Federica Pilotto, Deepika Chellapandi, Hélène Puccio, Omaveloxolone: a groundbreaking milestone as the first FDA-approved drug for Friedreich ataxia, Trends in Molecular Medicine.
2024
Hélène Puccio, Valentine Mosbach, A multiple animal and cellular models approach to study frataxin deficiency in Friedreich Ataxia, Biochim Biophys Acta Mol Cell Res 2024 Oct; 1871(7): 119809.
2023
Deepika Chellapandi, Valentine Mosbach, Marie Paschaki, Helene Puccio, Recent Advances on Therapeutic Approaches for Friedreich’s Ataxia: New Pharmacological Targets, Protein, and Gene Therapy, .
2022
Arnaud Jacquier, Julian Theuriet, Fanny Fontaine, Valentine Mosbach, Nicolas Lacoste, Shams Ribault,..., Homozygous COQ7 mutation: a new cause of potentially treatable distal hereditary motor neuropathy, Brain - A Journal of Neurology.
2022
Arnaud Jacquier, Julian Theuriet, Fanny Fontaine, Valentine Mosbach, Nicolas Lacoste, Shams Ribault,..., Homozygous COQ7 mutation: a new cause of potentially treatable distal hereditary motor neuropathy, Brain 2023 Aug; 146(8): 3470-3483.